Matsumoto K, Yamamoto J, Miura T
Second Department of Surgery, Mie University School of Medicine, Tsu-City, Japan.
Int J Colorectal Dis. 1993 Jul;8(2):103-5. doi: 10.1007/BF00299337.
Immunohistochemical staining for c-myc p62 oncoprotein (p62) was performed in 59 colorectal carcinomas using mouse monoclonal antibody against human c-myc protein (MYC1-6E10). The immunoreactivity for p62 was intense in 22 (37.3%), and weak in 37 (62.7%) of the tumors. Advanced disease and nodal metastasis were more frequently seen in tumors showing intense staining but the difference did not reach statistical significance. Sixteen patients have died of the disease but overall survival rates did not differ between patients with tumors showing intense staining and those with tumors showing weakly staining. In 50 patients undergoing grossly curative resection, local or distant metastasis developed in 15 patients. Immunoreactivity for p62 had no effect on the rate of recurrence or disease free survival rates in these 50 patients undergoing grossly curative resection. The present study revealed that the immunoreactivity for p62 had no prognostic value in colorectal carcinoma.
采用抗人c-myc蛋白的小鼠单克隆抗体(MYC1-6E10),对59例结直肠癌进行c-myc p62癌蛋白(p62)的免疫组化染色。在这些肿瘤中,22例(37.3%)的p62免疫反应性强,37例(62.7%)的免疫反应性弱。染色强的肿瘤中晚期疾病和淋巴结转移更常见,但差异无统计学意义。16例患者死于该疾病,但染色强的肿瘤患者与染色弱的肿瘤患者的总生存率无差异。在50例接受根治性切除术的患者中,15例出现局部或远处转移。p62的免疫反应性对这50例接受根治性切除术患者的复发率或无病生存率无影响。本研究表明,p62的免疫反应性在结直肠癌中无预后价值。